Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diabetes Care A Prime Target For Amazon

Executive Summary

Amazon's recent partnership with the Arcadia Group to supply blood glucose strips and meters under the new brand name Choice is another move by the retail giant to disrupt the health-care sector using the path of least resistance.

You may also be interested in...



Market Intel: Needle-Free Glucose Monitoring, Digital Solutions Are Game-Changers In Growing Diabetes-Monitoring Market

The global blood glucose monitoring devices market is expected to exceed $7bn by 2022, driven by the smaller, but fastest-growing continuous glucose monitoring (CGM) segment, which is expanding at double-digits. The much bigger blood glucose meter (BGM) segment, meanwhile, is facing increased competition from lower-cost manufacturers, innovative startups and tech giants like Apple that are attracting consumers with smart devices and packaged diabetes management solutions. This first of a two-part series looks more closely at the competitive landscape of the two major product segments – BGM and CGM – with insights from endocrinologists. The second part will focus on the pros and cons of using diabetes management apps and highlights the best diabetes apps.

Deal Watch: Amazon Moves Into Rx Services With Acquisition Of PillPack

Celgene makes play into RNA-expression correction via neuroscience partnership and equity investment with Skyhawk. Novartis’ Sandoz agreed to commercialize Adamis’ Symjepi, a competitor to EpiPen, in the US.

Mysterious Amazon/Berkshire/JPMorgan Partnership Could Disrupt Health Care, Pharma

The collective bargaining power of the three large employers, potentially assisted by Amazon's low-cost distribution channels, could be a formidable force in negotiating lower cost and better quality health care services, including pharmaceutical products.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT123504

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel